Vitiligo Clinical Trial: Efficacy of Red Light Treatment
Efficacy of Red Light Treatment for Vitiligo
Prospective single-blind randomized clinical trial to assess the efficacy of red light treatment in vitiligo. Visible red light has been shown to stimulate melanocyte migration and proliferation resulting in repigmentation of vitiligo.
Principal Investigator: Harvey Lui, MD FRCPC Co – Investigator
Mohammed I AlJasser, MD FRCPC
Study Location: The Skin Care Center, Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 4E8
• Must be a resident of Canada
• Must have localized or generalized vitiligo
• Must have a depigmented area 4 sq. inches (25 cm2) or larger, (excluding face, genitals, hands and feet) with no more than 10% repigmentation.
Exclusion Criteria:The following will not be eligible:
• Patients who received treatment for vitiligo within the past 3 weeks.
• Patients known to have a photosensitivity disorder
• Patients with a history of previous skin cancer
• Patients with a history of severe medical illness or immunosuppression
• Patients who are pregnant or breast-feeding
The vitiligo patch will be divided into 4 quadrants. One quadrant will receive low intensity red light, one high intensity red light, and the other two will be shielded and not receive any treatment. Treatments will be given twice weekly for 10 weeks, with assessments done every 2 weeks while receiving treatment, and at 4, 8, and 12 weeks post-treatment.
If you are interested in participating or would like more information:
Contact: Co-Investigator: Mohammed I AlJasser, MD, FRCPC
Phone: 1-778-859-5522 or Email: firstname.lastname@example.org